NCT01700322View on ClinicalTrials.gov

Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study

PHASE4CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

July 31, 2016

Study Completion Date

September 30, 2016

Conditions
Coronary Artery Disease
Interventions
PROCEDURE

Coronary stenting

All patients will receive a drug eluting stent as clinically indicated.

DRUG

Ticagrelor

Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting

DRUG

Clopidogrel

Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.

DRUG

Prasugrel

Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting

Trial Locations (1)

55131

2 Medical Clinic, Mainz

All Listed Sponsors
lead

Johannes Gutenberg University Mainz

OTHER

NCT01700322 - Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study | Biotech Hunter | Biotech Hunter